Results 61 to 70 of about 847 (163)

Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine

Medicine in Drug Discovery, 2020
Purpose: Current acute migraine treatment consists of migraine-specific agents, namely triptans, as well as non-specific analgesia, such as non-steroidal anti-inflammatory drugs and acetaminophen (paracetamol).
David Moreno-Ajona, Abigail Pérez-Rodríguez, Peter J. Goadsby   +2 more
doaj   +1 more source

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1525-1536, July/August 2026.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

Supplemental Material, sj-pdf-1-rep-10.1177_25158163231191582 - Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies

, 2023
Supplemental Material, sj-pdf-1-rep-10.1177_25158163231191582 for Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies by Ramesh Boinpally, Marleen Depré, Griet Van Lancker, Marissa F ...
Griet Van Lancker (4516501), Marissa F Dockendorf (11259651), Tom Reynders (16854351), Catherine Zhou Matthews (16854354), K Chris Min (16854357), Jean-Francois Denef (16854348), Marleen Depré (16854345), Joel M Trugman (9696784), Phung Bondiskey (2299597), Jan de Hoon (5261618), Ramesh Boinpally (8832245), Jialin Xu (40952)   +11 more
core   +1 more source

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik, Hua-Poo Su, Yacob Gomez Llorente, Rachel L. Palte, Daniel J. Klein, Robert P. Hayes, Sadie P. Antine, Guilermo A. Asmar-Rovira, Nicole Bertoletti, Noel J. Byrne, Brittany L. Carroll, Ciro D. Cordeiro, Kaylynn Curfman, James Dutko, Michael J. Eddins, Thierry Fischmann, Barani Govindarajan, Corey W. Hecksel, Thu Ho, Kaspar Hollenstein, Mee Ra Hong, Alan Hruza, Andrii Ishchenko, Maru Jaime-Garza, Matt J. Jaremko, Hayley L. Knox, James Kostas, Harini Krishnamurthy, Ioannis Manolaridis, Cameron L. Noland, Andrea T. Partridge, Sangita B. Patel, Paul Reichert, John C. Reid, Catarina Felisberto-Rodrigues, Chitra A. Shintre, Jennifer M. Shipman, Elakkiya Tamilselvan, Morgan E. Walker, Susanne N. Walker, Renjing Wang, Katharine M. Wright, Tien-Jui Yen, Byung-Kuk Yoo, Sandra B. Gabelli   +44 more
wiley   +1 more source

Process for the Purification of Atogepant [PDF]

The present disclosure relates to a process for the purification of Atogepant. Atogepant represented by the following structural formula-1.
, Srinivasan Thirumalai Rajan; MSN Laboratories Private Limited, R&D Center, Hyderabad
core  

sj-pdf-1-cep-10.1177_03331024211042385 - Supplemental material for Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

, 2021
Supplemental material, sj-pdf-1-cep-10.1177_03331024211042385 for Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial by Todd J Schwedt, Richard B Lipton, Jessica Ailani ...
Stephen D Silberstein (5323808), Cristina Tassorelli (665097), Richard B Lipton (7319192), Lawrence Severt (10680301), Jessica Ailani (7039019), Michelle Finnegan (11440947), Brett Dabruzzo (11440941), Joel M Trugman (9696784), Rosa Miceli (11440944), Todd J Schwedt (11440938), Hua Guo (305546), Kaifeng Lu (260953)   +11 more
core   +1 more source

Efectividad, tolerabilidad y seguridad de atogepant en vida real: un estudio observacional prospectivo multicéntrico del Grupo de Estudio de Cefaleas de Castilla-La Mancha

Neurología
Resumen: Introducción: La migraña es el motivo de consulta neurológica más frecuente, y conlleva un gran impacto a nivel laboral, social y económico para los pacientes que la padecen.
M. Calvo Alzola, J.A. Garrido Robres, E.F. Cano Vargas-Machuca, A. Ávila Fernández, A. Andrés López, M. Payá Montes, R.E. Ibáñez Alonso, J.M. Flores Barragán, N. Sánchez Cano, A.J. Castellano Vicente, S. Navarro Muñoz   +10 more
doaj   +1 more source

Safety and Efficacy of Atogepant for the Preventive Treatment of Migraines in Adults: A Systematic Review and Meta-Analysis

Background: Migraine is a common neurological condition marked by unilateral recurrent pulsating headaches, often associated with systemic signs and symptoms. Recently, calcitonin gene-related peptide (CGRP) antagonists, including atogepant, an oral CGRP
Abdulrahim Saleh Alrasheed, Majed Mohammad Alabdali, Reem Ali Alshamrani, Taif Mansour Almaqboul, Noor Mohammad AlMohish   +4 more
core   +1 more source

sj-pdf-4-cep-10.1177_03331024221128250 - Supplemental material for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial

, 2023
Supplemental material, sj-pdf-4-cep-10.1177_03331024221128250 for Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial by Brad C Klein,
Merle Diamond (9466484), Jennifer McVige (12525835), Michael J Marmura (5323802), Brad C Klein (14354870), Lawrence Severt (10680301), Peter McAllister (12057506), Michelle Finnegan (11440947), Joel M Trugman (9696784), Rosa Miceli (11440944), Hua Guo (305546), Laszlo Mechtler (14354873)   +10 more
core   +1 more source

Recomendaciones basadas en evidencia para el tratamiento preventivo de la migraña crónica. Asociación Colombiana de Neurología

Acta Neurológica Colombiana
Introducción: debido al impacto en la calidad de vida de las personas que la padecen y la carga a los sistemas de salud, la migraña crónica es una condición clínica de importancia en la población general. Objetivo: presentar recomendaciones basadas en
Joe Muñoz-Cerón, Yessika Rojas Villegas, Marta Ramos Romero, Stephania Bohorquez Valderrama, Carolina Guerra Posada, Juan Diego Jiménez Jaramillo, Natalia Hernández Beltrán, Oscar Enrique Pradilla Vesga, Sergio Ramírez García, Paula G. Cavanzo Henao, Reydmar López González, Claudia Marcela Moreno Rodríguez, José David Martínez Gaviria, Bernardo Uribe García, Fidel Ernesto Sobrino Mejía   +14 more
doaj   +1 more source